Table 1.

Clinical baseline characteristics of the patients and PLA2R antibody levels at the time of study inclusion and at the start of immunosuppression

CharacteristicsWhole Patient CohortInitial Immunosuppressive Therapy
None (No IS)CNIAlkRTX
Patients (n)1333254359
Sex, ratio of men to women (% men)101/32 (76)25/7 (78)42/12 (78)27/8 (77)5/4 (56)
Age (yr)54.4±15.257.1±12.151.4±17.456.2±13.155.2±15.5
Time from renal biopsy to first serum measurement (mo)1.2±1.51.0±1.41.2±1.41.3±1.61.4±2.0
Time from first serum measurement to start of IS treatment (mo)2.4±3.23.0±3.22.8±3.7
Proteinuria (g/24 h)
 At the time of first serum measurement9.6±5.07.4±3.29.9±5.4a11.8±5.4a8.5±4.2
 At 3 mo (no IS) or start of IS7.3±3.010.2±5.8a10.9±5.1a8.2±4.1
Serum albumin (g/L)
 At the time of first serum measurement23.7±4.125.0±3.522.8±4.6a23.8±3.424.0±3.3
 At 3 mo (no IS) or start of IS26.9±4.623.3±4.8a23.7±4.2a24.8±7.3
Serum creatinine (mg/dl)
 At the time of first serum measurement1.2±0.61.1±0.61.2±0.51.3±0.61.2±0.4
 At 3 mo (no IS) or start of IS1.3±0.91.2±0.51.3±0.61.2±0.5
PLA2R antibody level (total IgG ELISA)
 At the time of first serum measurement282±355218±276334±383310±411109±92
 At 3 mo (no IS) or start of IS137±165240±250311±439133±130
PLA2R antibody level (IgG4 ELISA)
 At the time of first serum measurement40±5332±4552±6339±4915±11
 At 3 mo (no IS) or start of IS16±2338±47a39±5223±30
  • There were no significant differences in any of the clinical characteristics between patients treated with calcineurin inhibitors, alkylating agents, or rituximab at the first serum measurement (study inclusion) or at the start of immunosuppression. There were no significant changes in the PLA2R antibody levels, proteinuria, or any other clinical characteristic from the time of first serum measurement to the start of immunosuppression. There were statistically significant differences in proteinuria, PLA2R antibody levels, and serum albumin between patients on supportive care only and patients who received immunosuppression (P<0.05). —, not applicable; IS, immunosuppression; CNI, calcineurin inhibitor; Alk, alkylating agent; RTX, rituximab.

  • a P<0.05.